{"id":"https://openalex.org/W4367603510","doi":"https://doi.org/10.1158/1557-3125.ras23-a003","title":"Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) with activating KRAS mutations","display_name":"Abstract A003: COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in patients with metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC), and colorectal cancer (CRC) with activating KRAS mutations","publication_year":2023,"publication_date":"2023-05-01","ids":{"openalex":"https://openalex.org/W4367603510","doi":"https://doi.org/10.1158/1557-3125.ras23-a003"},"language":"en","primary_location":{"id":"doi:10.1158/1557-3125.ras23-a003","doi":"https://doi.org/10.1158/1557-3125.ras23-a003","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1557-3125.ras23-a003","pdf_url":null,"source":{"id":"https://openalex.org/S192067876","display_name":"Molecular Cancer Research","issn_l":"1541-7786","issn":["1541-7786","1557-3125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062531028","display_name":"Stacey A. Cohen","orcid":"https://orcid.org/0000-0002-6207-9856","observed_orcids":["https://orcid.org/0000-0002-6207-9856"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stacey A. Cohen","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, WA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, WA,","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033837903","display_name":"Christos K Fountzilas","orcid":"https://orcid.org/0000-0003-3837-5644","observed_orcids":["https://orcid.org/0000-0003-3837-5644"]},"institutions":[{"id":"https://openalex.org/I1292894508","display_name":"Roswell Park Comprehensive Cancer Center","ror":"https://ror.org/0499dwk57","country_code":"US","type":"facility","lineage":["https://openalex.org/I1292894508"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christos Fountzilas","raw_affiliation_strings":["2Roswell Park Comprehensive Cancer Center, Buffalo, NY,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Roswell Park Comprehensive Cancer Center, Buffalo, NY,","institution_ids":["https://openalex.org/I1292894508"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063897579","display_name":"David Sommerhalder","orcid":"https://orcid.org/0000-0002-7033-9064","observed_orcids":["https://orcid.org/0000-0002-7033-9064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David Sommerhalder","raw_affiliation_strings":["3NEXT Oncology, San Antonio, TX,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3NEXT Oncology, San Antonio, TX,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070734531","display_name":"Sandip Pravin Patel","orcid":"https://orcid.org/0000-0002-8387-4840","observed_orcids":["https://orcid.org/0000-0002-8387-4840","https://orcid.org/0000-0002-4954-4944"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandip Patel","raw_affiliation_strings":["4UCSD, La Jolla, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4UCSD, La Jolla, CA,","institution_ids":["https://openalex.org/I36258959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051472920","display_name":"Ai Benson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210147348","display_name":"Northwestern Medicine","ror":"https://ror.org/04fzwnh64","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ai Benson","raw_affiliation_strings":["5Northwestern Medical Group, Chicago, IL,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Northwestern Medical Group, Chicago, IL,","institution_ids":["https://openalex.org/I4210147348"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100700364","display_name":"Kai He","orcid":"https://orcid.org/0000-0001-9905-5906","observed_orcids":["https://orcid.org/0000-0001-9905-5906"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kai He","raw_affiliation_strings":["6Ohio State University, Columbus, OH,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Ohio State University, Columbus, OH,","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024497224","display_name":"Apar Kishor Ganti","orcid":"https://orcid.org/0000-0003-3724-2671","observed_orcids":["https://orcid.org/0000-0003-3724-2671"]},"institutions":[{"id":"https://openalex.org/I122266389","display_name":"University of Nebraska at Omaha","ror":"https://ror.org/04yrkc140","country_code":"US","type":"education","lineage":["https://openalex.org/I122266389"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apar Ganti","raw_affiliation_strings":["7University of Nebraska, Omaha, NE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7University of Nebraska, Omaha, NE,","institution_ids":["https://openalex.org/I122266389"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044613951","display_name":"Alexander I. Spira","orcid":"https://orcid.org/0000-0003-1303-0447","observed_orcids":["https://orcid.org/0000-0003-1303-0447"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Spira","raw_affiliation_strings":["8NEXT Oncology, Virginia, Fairfax, VA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8NEXT Oncology, Virginia, Fairfax, VA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049754139","display_name":"Bhagyashree Yadav","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bhagyashree (Kelshikar) Yadav","raw_affiliation_strings":["9Biomea Fusion, Inc., Redwood City, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Biomea Fusion, Inc., Redwood City, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045278067","display_name":"Alex Cacovean","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex Cacovean","raw_affiliation_strings":["9Biomea Fusion, Inc., Redwood City, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Biomea Fusion, Inc., Redwood City, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047967518","display_name":"Steve Morris","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steve Morris","raw_affiliation_strings":["9Biomea Fusion, Inc., Redwood City, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Biomea Fusion, Inc., Redwood City, CA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Tom Butler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tom Butler","raw_affiliation_strings":["9Biomea Fusion, Inc., Redwood City, CA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Biomea Fusion, Inc., Redwood City, CA,","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Hong","raw_affiliation_strings":["10MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"21","issue":"5_Supplement","first_page":"A003","last_page":"A003"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.39890000224113464,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.39890000224113464,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.20000000298023224,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.052400000393390656,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/menin-inhibitors","display_name":"menin inhibitors","score":0.8080000281333923},{"id":"https://openalex.org/keywords/covalent-inhibitors","display_name":"covalent inhibitors","score":0.8299999833106995},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.7179999947547913},{"id":"https://openalex.org/keywords/metastatic-nsclc","display_name":"metastatic non-small cell lung cancer","score":0.9359999895095825},{"id":"https://openalex.org/keywords/pancreatic-ductal-adenocarcinoma","display_name":"pancreatic ductal adenocarcinoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.996999979019165},{"id":"https://openalex.org/keywords/jund","display_name":"JunD","score":0.8230000138282776},{"id":"https://openalex.org/keywords/rasgrf1","display_name":"RASGRF1","score":0.953000009059906},{"id":"https://openalex.org/keywords/ras-gtp","display_name":"Ras-GTP","score":0.5950000286102295},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6790000200271606},{"id":"https://openalex.org/keywords/oral-anticancer-drugs","display_name":"oral anticancer drugs","score":0.6769999861717224},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7129999995231628}],"concepts":[{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.9530946016311646},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6320838928222656},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5895495414733887},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.5879567265510559},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5453653931617737},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.47242724895477295},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.4446307122707367},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43129459023475647}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1557-3125.ras23-a003","doi":"https://doi.org/10.1158/1557-3125.ras23-a003","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1557-3125.ras23-a003","pdf_url":null,"source":{"id":"https://openalex.org/S192067876","display_name":"Molecular Cancer Research","issn_l":"1541-7786","issn":["1541-7786","1557-3125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4391095738","https://openalex.org/W4388045243","https://openalex.org/W4393088173","https://openalex.org/W4282964927","https://openalex.org/W4390915101","https://openalex.org/W2500811853","https://openalex.org/W4409633147","https://openalex.org/W3011515990","https://openalex.org/W4245050036","https://openalex.org/W7148778456"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"BMF-219":[2,52,91,100,136,178,351],"is":[3,73,107,117,338,408],"a":[4,10,57,118,169,173],"selective":[5],"covalent":[6,458],"inhibitor":[7,314,328],"of":[8,13,29,38,47,64,70,77,82,85,96,109,132,135,198,235,261,282,350,358,363,368,375,384,398,415,454,484],"menin,":[9],"transcriptional":[11],"regulator":[12],"oncogenic":[14,98],"signaling":[15],"pathways":[16],"in":[17,139,206,405,413,461],"multiple":[18],"cancers,":[19],"that":[20,106],"inhibits":[21],"the":[22,27,48,65,78,110,126,199,341,364,399,406,485],"menin/MYC":[23],"interaction":[24],"and":[25,31,88,129,214,330,366,370,473],"downregulates":[26],"expression":[28,69],"MYC":[30,32,44],"target":[33],"genes,":[34],"including":[35,237,263,284],"KRAS.":[36],"Mechanism":[37],"Action":[39],"(hypothesis):":[40],"In":[41],"addition":[42],"to":[43,210,339,393,410],"disruption,":[45],"inhibition":[46],"Menin-MLL":[49,66],"complex":[50,67],"by":[51,307],"alters":[53],"JunD":[54],"genomic":[55],"function,":[56],"crucial":[58],"factor":[59],"for":[60,75],"KRAS-driven":[61],"tumorigenesis.":[62,89],"Inhibition":[63],"suppresses":[68],"Rasgrf1,":[71],"which":[72],"essential":[74],"generation":[76],"active":[79],"RAS-GTP":[80],"conformation":[81],"KRAS,":[83],"activation":[84],"downstream":[86],"pathways,":[87],"Preclinically,":[90],"shows":[92],"sustained":[93],"potent":[94],"abrogation":[95],"menin-dependent":[97],"signaling.":[99],"exerts":[101],"pan-mutant":[102],"KRAS":[103,159,223,313,479],"anticancer":[104],"activity":[105,131],"independent":[108],"specific":[111],"KRAS-activating":[112],"mutation.":[113],"Methods:":[114],"COVALENT-102":[115],"(NCT05631574)":[116],"prospective,":[119],"open-label,":[120],"multicenter,":[121],"dose":[122,175,344,348,451],"finding":[123,452],"study":[124,407,453],"evaluating":[125],"safety,":[127],"tolerability,":[128,361],"clinical":[130],"escalating":[133],"doses":[134],"administered":[137,181],"daily":[138,183],"patients":[140,205,218,462],"with":[141,157,221,231,247,256,277,311,463,477],"unresectable,":[142],"locally":[143],"advanced,":[144],"or":[145,193,266,271,286],"metastatic":[146,464],"NSCLC":[147,230],"(Cohort":[148,151,155,226,251,272],"1),":[149],"PDAC":[150,255],"2)":[152,252],"&":[153,225,302,360,378,391],"CRC":[154,276],"3)":[156,273],"activating":[158,478],"mutations":[160,480],"who":[161],"have":[162,299],"received":[163],"standard":[164],"therapy.":[165],"All":[166],"indications":[167],"as":[168,184,187,305],"group":[170],"will":[171,179,203],"follow":[172],"3+3":[174],"escalation":[176],"design.":[177],"be":[180,411],"orally":[182],"continuous":[185],"therapy":[186,236,262,283],"28-days":[188],"treatment":[189],"cycle":[190],"until":[191],"progression":[192,301],"intolerability/unacceptable":[194],"toxicity.":[195],"Following":[196],"conclusion":[197],"dose-escalation,":[200],"each":[201],"indication":[202],"enroll":[204],"expansion":[207],"cohorts":[208],"independently":[209],"obtain":[211],"further":[212,356],"safety":[213,359],"efficacy":[215,371],"data.":[216],"Eligible":[217],"include":[219,321,355],"those":[220],"any":[222],"mutation":[224],"1)":[227],"stage":[228,253,274],"IIIB/IV":[229],"2-4":[232],"prior":[233,259,280,312,326],"lines":[234],"immune":[238],"checkpoint":[239],"inhibitors":[240],"(ICI)":[241],"&/or":[242],"platinum-based":[243],"chemo":[244],"\u00b1":[245,288],"bevacizumab":[246,289],"ECOG":[248,268,294],"PS":[249,269,295],"0-2;":[250],"III/IV":[254,275],"\u2265":[257,278],"1":[258,279],"line":[260,281],"either":[264],"FOLFIRINOX":[265],"gemcitabine/nab-paclitaxel,":[267],"0-1;":[270],"FOLFOX":[285],"FOLFIRI":[287],"(prior":[290],"ICI":[291],"if":[292],"MSI-H/dMMR),":[293],"0-2.":[296],"Patients":[297,310],"must":[298],"documented":[300],"measurable":[303],"disease":[304,379],"defined":[306],"RECIST":[308],"1.1.":[309],"exposure":[315],"are":[316,396],"eligible.":[317],"Key":[318],"exclusion":[319],"criteria":[320],"symptomatic":[322],"&/untreated":[323],"CNS":[324],"metastasis,":[325],"menin":[327,459],"therapy,":[329],"clinically":[331],"significant":[332],"cardiovascular":[333],"disease.":[334],"The":[335,402],"primary":[336],"objective":[337],"determine":[340],"optimal":[342],"biological":[343],"(OBD)/recommended":[345],"Phase":[346],"2":[347],"(RP2D)":[349],"monotherapy.":[352],"Secondary":[353],"objectives":[354],"evaluation":[357],"characterization":[362],"pharmacodynamics":[365],"pharmacokinetics":[367],"BMF-219,":[369,455],"based":[372],"on":[373],"duration":[374],"response":[376,394],"(DOR)":[377],"control":[380],"rate":[381],"(DCR).":[382],"Assessment":[383],"progression-free":[385],"survival":[386,389],"(PFS),":[387],"overall":[388],"(OS)":[390],"time":[392],"(TTR)":[395],"part":[397],"exploratory":[400],"endpoints.":[401],"first":[403],"patient":[404],"anticipated":[409],"dosed":[412],"Q4":[414],"2022.":[416],"Citation":[417],"Format:":[418],"Stacey":[419],"A.":[420],"Cohen,":[421],"Christos":[422],"Fountzilas,":[423],"David":[424,445],"Sommerhalder,":[425],"Sandip":[426],"Patel,":[427],"Ai":[428],"Benson,":[429],"Kai":[430],"He,":[431],"Apar":[432],"Ganti,":[433],"Alex":[434,439],"Spira,":[435],"Bhagyashree":[436],"(Kelshikar)":[437],"Yadav,":[438],"Cacovean,":[440],"Steve":[441],"Morris,":[442],"Tom":[443],"Butler,":[444],"Hong.":[446],"COVALENT-102:":[447],"A":[448],"phase":[449],"1/1b":[450],"an":[456],"oral":[457],"inhibitor,":[460],"non-small":[465],"cell":[466],"lung":[467],"cancer":[468,471,475],"(NSCLC),":[469],"pancreatic":[470],"(PDAC),":[472],"colorectal":[474],"(CRC)":[476],"[abstract].":[481],"In:":[482],"Proceedings":[483],"AACR":[486],"Special":[487],"Conference:":[488],"Targeting":[489],"RAS;":[490],"2023":[491],"Mar":[492],"5-8;":[493],"Philadelphia,":[494],"PA.":[495],"Philadelphia":[496],"(PA):":[497],"AACR;":[498],"Mol":[499],"Cancer":[500],"Res":[501],"2023;21(5_Suppl):Abstract":[502],"nr":[503],"A003.":[504]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2023-05-02T00:00:00"}